Placement raises up to A$0.5 million and transaction update
Released
Released
Announcement PDF
1
AdAlta Limited (ASX:1AD) · ABN: 92 120 332 925 · www.adalta.com.au
LIMS2 204, La Trobe Institute of Molecular Science, La Trobe University VIC 3086, Australia
ASX Announcement | 13 October 2025
AdAlta Limited (ASX:1AD)
Premium priced placement raises up to A$0.5 million;
transaction update
Non-brokered private placement to strategic investor strengthens AdAlta’s
ability to close cellular immunotherapy transactions
Investment highlights
• AdAlta has received a firm commitment to raise A$0.5 million from a new Hong Kong based
sophisticated investor (subject to shareholder approval in respect to part), vis a non-brokered
private placement
• Issue Price of 0.3c per share ($0.003) represents a 20% premium to closing price on 10 October
• Company will issue Subscription Shares under and Attaching Options on the same terms as the
recent fully subscribed Entitlement Offer
• Proceeds to strengthen AdAlta’s position as it advances “East to West” cellular immunotherapy
transactions and other strategic options
AdAlta Limited (ASX:1AD) (“AdAlta” or “the Company”), developer of next generation cell and protein
therapeutic products has raised up to A$0.5 million in a private, company facilitated placement from Hong
Kong based sophisticated investor, David Pevcic. The proceeds will strengthen AdAlta’s position as it seeks
to execute forecast transactions under its “East to West” cellular immunotherapy strategy and evaluate other
strategic opportunities.
AdAlta CEO and Managing Director, Tim Oldham said: "This unsolicited investment is strong validation of
our “East to West” cellular immunotherapy strategy and the potential for Asian innovation to deliver better
outcomes for cancer patients globally. These funds will materially strengthen our position as we advance
licensing and private financing transactions as part of this strategy. We welcome another significant new
investor to our register and thank them for their support."
$0.5 million placement at premium to market
The placement to a single sophisticated investor will raise up to $0.5 million. There are no material costs of
the offer and no broker fees are payable.
The issue price of 0.3c per share represents a 20% premium to the closing price on 12 October of 0.25c and
a 25% premium to the 5 day VWAP of 0.24c.
Placement strengthen’s AdAlta’s position to execute growth transactions
AdAlta is executing its “East to West” cellular immunotherapy strategy under which it aims to bring the
enormous potential of CAR-T cell therapies to solid cancer patients globally by licensing highly innovative
clinical stage products developed in Asia, and in particular the new powerhouse of global biotechnology
innovation, China, and developing them for global markets.
AdAlta is making significant progress on agreeing the terms of the definitive development and collaboration
agreement for its first CAR-T cell therapy asset. Finalising this agreement will be subject to AdAlta securing
the funds required for the first stage of the collaboration. AdAlta is in active discussions with multiple private
investors from around the world who are evaluating the potential to invest in its “East to West” cellular
immunotherapy subsidiary. Discussions for a second licensing agreement continue to advance.
AdAlta has also been presented with at several other strategic licensing opportunities in adjacent fields and
continues to evaluate the most compelling of these.
2
In addition to strengthening its working capital position as it negotiates these transactions, the proceeds of
this placement may enable AdAlta to contribute funds to increase its share of the “East to West” opportunity;
advance other transaction opportunities in parallel instead of in sequence; and extend or expand intellectual
property associated with its existing i-body-enabled assets.
Placement terms the same as recent Entitlement Offer; part subject to shareholder approval
The terms of the placement are materially the same as the recent fully subscribed Entitlement Offer (ASX
announcements on 3 June and 13 June 2025). The Company will, subject to shareholder approval in part,
issue 166,666,667 new fully paid ordinary shares (“Subscription Shares”) at a price of $0.003 and
83,333,334 new options (one for every two Subscription Shares issued) exercisable at $0.01, with expiry
date of 3 June 2028 (“Attaching Options”). The Attaching Options form part of the existing class of listed
options trading under the ticker ASX:1ADO.
153,657,204 Subscription Shares (raising approximately $460,972) will be issued upon receipt of cash
expected to be on 17 October 2025 under the Company’s available capacity under Listing Rule 7.1A. The
remaining 13,009,463 Subscription Shares and the 83,333,334 Attaching Options will be issued, subject to
shareholder approval, after the Company’s forthcoming Annual General Meeting in November, 2025.
To view a summary and engage in discussion about this announcement visit AdAlta’s InvestorHub here:
https://investorhub.adalta.com.au/link/P2zn3P
This ASX announcement has been authorised for release by the Board of AdAlta Limited (ASX:1AD).
For further information, please contact:
AdAlta Limited (ASX:1AD)
Tim Oldham
CEO & Managing Director
P: +61 403 446 665
E: ir@adalta.com.au
About AdAlta
AdAlta (ASX: 1AD) is a clinical stage biotechnology business addressing the need for effective cellular
immunotherapies for the treatment of solid cancers.
Through its ‘East to West’ strategy, the Company is integrating Asia's prowess in T cell therapy development
with the efficiency and quality of Australia's clinical and manufacturing ecosystem to create a pathway
connecting ‘Eastern’ innovation in cellular immunotherapies with ‘Western’ regulated markets and patients.
AdAlta in-licenses products from Asian originators and invests to establish US FDA regulated manufacturing
and conduct Phase I clinical studies with potential to position each product for on-licensing to larger
biopharmaceutical companies for potential registrational studies and commercialization.
AdAlta implements a disciplined approach to asset selection focused on highly differentiated T cell therapy
products supported by clinical data in solid cancers. The company adopts a capital efficient business model
delivering a rapid return on investment in each project that is replicable and provides opportunities to scale
across multiple products.
Solid tumours account for 90% of cancers yet remain underserved by current cellular immunotherapies.
AdAlta aims to dominate this high-growth segment. The cellular immunotherapy market is projected to grow
at a compound annual growth rate of 34% to reach US$20.3 billion by 2028.
AdAlta’s first in class fusion protein, AD-214, takes a whole new approach to fibrotic diseases of the lung and
kidney, such as the degenerative and fatal Idiopathic Pulmonary Fibrosis. Following demonstration of
efficacy in multiple animal models of disease and two successful Phase I clinical studies, AD-214 is available
for partnering.
3
To learn more, please visit: www.adalta.com.au
For more information
Join our InvestorHub
Follow us on LinkedIn
Follow us on X (formerly Twitter)
Share your feedback
Discover